GRAL — GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 1,000
- Website: https://grail.com
Latest SEC filings for GRAL
- SCHEDULE 13G/A — 2026-08-13
- SCHEDULE 13G — 2026-08-07
- SCHEDULE 13G/A — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-08-05
- 8-K — 2026-06-22
- 8-K — 2026-06-01
- SCHEDULE 13G/A — 2026-05-15
- SCHEDULE 13G/A — 2026-05-11
- 10-Q — 2026-05-07
Latest GRAL news
- — First-Class Amenity Kits Have Become Holy Grail Collectibles (wsj.com)
- — Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
- — Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. (fool.com)
- — 2 Growth Stocks to Buy in October
- — Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
- — GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 (prnewswire.com)
- — Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? (fool.com)
- — GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?
- — GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?
- — 3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
Educational tool only — not investment advice.